Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations.

[1]  A B Kay,et al.  Allergy and allergic diseases. First of two parts. , 2001, The New England journal of medicine.

[2]  R. V. van Neerven,et al.  Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. , 1999, Journal of immunology.

[3]  L. Klimek,et al.  Tree‐pollen allergy is efficiently treated by short‐term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens , 1998, Allergy.

[4]  S. Durham,et al.  Immunologic changes associated with allergen immunotherapy. , 1998, The Journal of allergy and clinical immunology.

[5]  C. Akdis,et al.  Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.

[6]  Giorgio Walter Canonica,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases , 1998 .

[7]  R. Valenta,et al.  Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. , 1998, Journal of immunology.

[8]  H. Løwenstein,et al.  Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long‐term (6‐year) follow‐up , 1997, Allergy.

[9]  J. Tonascia,et al.  A controlled trial of immunotherapy for asthma in allergic children. , 1997, The New England journal of medicine.

[10]  J. Banchereau,et al.  Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. , 1996, Journal of immunology.

[11]  C. Martínez-Cócera,et al.  A double‐blind, placebo‐controlled study of immunotherapy with grass‐pollen extract Alutard SQ during a 3–year period with initial rush immunotherapy , 1996, Allergy.

[12]  D. Tinkelman,et al.  Compliance with an allergen immunotherapy regime. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  D. Umetsu,et al.  Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals , 1993, The Journal of experimental medicine.

[14]  S. Durham,et al.  Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. , 1993, The Journal of clinical investigation.

[15]  J. Cohn,et al.  Determinants of patient compliance with allergen immunotherapy. , 1993, The Journal of allergy and clinical immunology.

[16]  E. Pastorello,et al.  Clinical and immunological effects of immunotherapy with alum‐absorbed grass allergoid in grass‐pollen‐induced hay fever , 1992, Allergy.

[17]  J. Bousquet,et al.  Systemic reactions occurring during immunotherapy with standardized pollen extracts. , 1992, The Journal of allergy and clinical immunology.

[18]  J. Bousquet,et al.  Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. , 1991, The Journal of allergy and clinical immunology.

[19]  J. Bousquet,et al.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. , 1988, The Journal of allergy and clinical immunology.

[20]  B. Davies,et al.  Immunological changes associated with a successful outcome of pollen immunotherapy , 1988, Allergy.

[21]  H. Ipsen,et al.  Immunotherapy with partially purified and standardized tree pollen extracts , 1988, Allergy.

[22]  R. Einarsson,et al.  Immunotherapy to deciduous tree pollens: specific IgE and IgG antibody patterns , 1987, Clinical allergy.

[23]  J. Bousquet,et al.  Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. , 1987, The Journal of allergy and clinical immunology.

[24]  R. Djurup,et al.  High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens , 1987, Clinical allergy.

[25]  R. Lockey,et al.  Fatalities from immunotherapy (IT) and skin testing (ST) , 1987, The Journal of allergy and clinical immunology.

[26]  R. Moss,et al.  Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. , 1986, The Journal of allergy and clinical immunology.

[27]  R. Djurup,et al.  The Subclass Nature and Clinical Significance of the IgG Antibody Response in Patients Undergoing Allergen‐Specific Immunotherapy , 1985, Allergy.

[28]  E. Pastorello,et al.  Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. , 1984, The Journal of allergy and clinical immunology.

[29]  L. Lichtenstein,et al.  Immunologic and cellular changes accompanying the therapy of pollen allergy. , 1971, The Journal of clinical investigation.